Torisel (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Torisel (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Torisel (Renal Cell Carcinoma)- Analysis and Forecasts to 2020' provides Torisel sales
forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales,
competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes
information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData's proprietary
databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured
press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's
team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Torisel including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Torisel including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 20006-2020 for Torisel in the US, EU5 and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4

Torisel (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020 (From Slideshare) Page 1/7


2.1 RCC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Obesity 6
2.3.3 Acquired Cystic Disease 6
2.3.4 Hypertension 6
2.4 GlobalData Report Guidance 7
3 RCC Disease: Market Characterization 8
3.1 RCC Disease Market 8
3.2 RCC Disease Market Forecasts and CAGR 8
3.3 Drivers for the RCC Disease Market 9
3.3.1 High Incidence 9
3.3.2 High Prevalence 10
3.3.3 Emergence of Targeted Therapies 10
3.3.4 Large Unmet Need 10
4 Tumor-Node-Metastases (TNM) Classification of RCC 11
5 Torisel 14
5.1 Introduction 14
5.2 Mechanism of Action 14
5.3 Clinical Study 14
5.4 Approval History of Torisel 15
5.5 Factors Affecting Sales of Torisel 16
5.5.1 RCC Market 16
5.5.2 Unmet Need 16
5.5.3 Use in combination 16
5.5.4 Efficacy 16
5.5.5 Increasing use of Torisel in Second Line and Third Line Treatment 16
5.5.6 Syergy Effect of Merger 16
5.5.7 Crowded Market 16
5.6 Drug Risk Benefit Score (DRB) 17
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intesity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Torisel 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Torisel 20
6 RCC Market: Appendix 30
6.1 Market Definitions 30
6.2 Abbreviations 30
6.3 Research Methodology 30
6.3.1 Coverage 31
6.3.2 Secondary Research 31



6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.8 Primary Research 33
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 RCC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Obesity 6
2.3.3 Acquired Cystic Disease 6
2.3.4 Hypertension 6
2.4 GlobalData Report Guidance 7
3 RCC Disease: Market Characterization 8
3.1 RCC Disease Market 8
3.2 RCC Disease Market Forecasts and CAGR 8
3.3 Drivers for the RCC Disease Market 9
3.3.1 High Incidence 9
3.3.2 High Prevalence 10
3.3.3 Emergence of Targeted Therapies 10
3.3.4 Large Unmet Need 10
4 Tumor-Node-Metastases (TNM) Classification of RCC 11
5 Torisel 14
5.1 Introduction 14
5.2 Mechanism of Action 14
5.3 Clinical Study 14
5.4 Approval History of Torisel 15
5.5 Factors Affecting Sales of Torisel 16
5.5.1 RCC Market 16
5.5.2 Unmet Need 16
5.5.3 Use in combination 16
5.5.4 Efficacy 16
5.5.5 Increasing use of Torisel in Second Line and Third Line Treatment 16
5.5.6 Syergy Effect of Merger 16
5.5.7 Crowded Market 16
5.6 Drug Risk Benefit Score (DRB) 17
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intesity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Torisel 18



5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.5 Sales Projections of Torisel 20
6 RCC Market: Appendix 30
6.1 Market Definitions 30
6.2 Abbreviations 30
6.3 Research Methodology 30
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 34
6.5 Disclaimer 34
6.6 Sources 34

1.1 List of Tables

Table 1: RCC, Incidences and Mortality, 2008-2030 5
Table 2: RCC, Global, Market Forecast ($bn), 2002'2020 8
Table 3: Summary of Efficacy Results of TORISEL vs. IFN-' 15
Table 4: Drug Risk Benefit Score 17
Table 5: RCC, The US, EU-5 and Japan, Sales Forecast for Torisel ($m), 2007'2020 21
Table 6: RCC, The US, Sales Forecast for Torisel ($m), 2007'2020 22
Table 7: RCC, The UK, Sales Forecast for Torisel ($m), 2008'2020 23
Table 8: RCC, France, Sales Forecast for Torisel ($m), 2008'2020 24
Table 9: RCC, Germany, Sales Forecast for Torisel ($m), 2008'2020 25
Table 10: RCC, Italy, Sales Forecast for Torisel ($m), 2008'2020 26
Table 11: RCC, Spain, Sales Forecast for Torisel ($m), 2008'2020 27
Table 12: RCC, Japan, Sales Forecast for Torisel ($m), 2011'2020 28

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: % Difference of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: RCC, Global Market Size Forecasts ($bn), 2009-2020 8
Figure 5: Oncology, Global, Estimated Incidence 2008-2030 9
Figure 6: RCC, Global, Estimated Incidence 2008-2030 9
Figure 7: Broad Classification of Kidney Cancer 11
Figure 8: Detailed TNM Classifications of RCC 12
Figure 9: Classification of RCC (US, EU except the UK and Japan) 13
Figure 10: Classification of RCC ( The UK) 13



Figure 11: Results from a phase III study conducted in 626 previously untreated patients with advanced RCC 15
Figure 12: Drug Model Diagram of Torisel for the US, the EU (except the UK) and Japan 19
Figure 13: Drug Model Diagram of Torisel for the UK 19
Figure 14: Drug Dosage Diagram of Torisel 20
Figure 15: RCC, The US, EU-5 and Japan, Sales Forecast for Torisel ($m), 2007'2020 21
Figure 16: RCC, The US, Sales Forecast for Torisel ($m), 2007'2020 22
Figure 17: RCC, The UK, Sales Forecast for Torisel ($m), 2008'2020 23
Figure 18: RCC, France, Sales Forecast for Torisel ($m), 2008'2020 24
Figure 19: RCC, Germany, Sales Forecast for Torisel ($m), 2008'2020 25
Figure 20: RCC, Italy, Sales Forecast for Torisel ($m), 2008'2020 26
Figure 21: RCC, Spain, Sales Forecast for Torisel ($m), 2008'2020 27
Figure 22: RCC, Japan, Sales Forecast for Torisel ($m), 2011'2020 28
Figure 23: Torisel, RCC, Sales Forecast by Country ($m), 2020 29
Figure 24: GlobalData Methodology 30
Figure 25: Drug Model Diagram 32
Figure 26: Patients Approved for the Drug 33


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Torisel (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (17)

More from ReportLinker.com

More from ReportLinker.com (20)

Torisel (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020